The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia

[1]  John G Doench,et al.  MEN1 mutations mediate clinical resistance to menin inhibition , 2023, Nature.

[2]  S. Armstrong,et al.  The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML , 2021, Blood.

[3]  M. Konopleva,et al.  Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements , 2021, Blood Cancer Journal.

[4]  M. Andreeff,et al.  Therapeutic implications of menin inhibition in acute leukemias , 2021, Leukemia.

[5]  H. Xie,et al.  Menin is necessary for long term maintenance of meningioma-1 driven leukemia , 2021, Leukemia.

[6]  C. Bloomfield,et al.  Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/KMT2A , 2020, Proceedings of the National Academy of Sciences.

[7]  S. Armstrong,et al.  Synergistic Targeting of FLT3 Mutations in AML via Combined Menin-MLL and FLT3 Inhibition. , 2020, Blood.

[8]  Sarah E. Dorff,et al.  Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis , 2020, Clinical Cancer Research.

[9]  S. Armstrong,et al.  Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia , 2020, Science.

[10]  K. Ross,et al.  A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia. , 2019, Cancer cell.

[11]  I. Kline,et al.  Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study , 2018, JAMA oncology.

[12]  R. Collins,et al.  Durable Remissions with Ivosidenib in IDH1‐Mutated Relapsed or Refractory AML , 2018, The New England journal of medicine.

[13]  I. Flinn,et al.  Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. , 2017, Blood.

[14]  Bob Löwenberg,et al.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.

[15]  Nicola D. Roberts,et al.  Genomic Classification and Prognosis in Acute Myeloid Leukemia. , 2016, The New England journal of medicine.

[16]  M. Sanz,et al.  How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia. , 2014, Blood.

[17]  Robert K Hills,et al.  Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Bob Löwenberg,et al.  High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Paola Fazi,et al.  Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. , 2013, The New England journal of medicine.

[20]  Jolanta Grembecka,et al.  Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. , 2012, Nature chemical biology.

[21]  F. Lo‐Coco,et al.  Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Jeffrey S Barrett,et al.  Shortening the timeline of pediatric phase I trials: the rolling six design. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Scott A. Armstrong,et al.  MLL translocations, histone modifications and leukaemia stem-cell development , 2007, Nature Reviews Cancer.

[24]  R. Pieters,et al.  A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial , 2007, The Lancet.

[25]  F. Lo‐Coco,et al.  The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia , 2006, Leukemia.

[26]  N. Heerema,et al.  Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group. , 2006, Blood.

[27]  Matthew Meyerson,et al.  The Menin Tumor Suppressor Protein Is an Essential Oncogenic Cofactor for MLL-Associated Leukemogenesis , 2005, Cell.

[28]  Unnur Thorsteinsdottir,et al.  Defining Roles for HOX and MEIS1 Genes in Induction of Acute Myeloid Leukemia , 2001, Molecular and Cellular Biology.

[29]  S. Korsmeyer,et al.  Altered Hox expression and segmental identity in Mll-mutant mice , 1995, Nature.

[30]  J. Michaeli,et al.  Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent. , 1992, Blood.

[31]  S. Armstrong,et al.  Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia. , 2016, Cancer discovery.